Celldex Therapeutics, Inc. (CLDX) FY2025 10-K Annual Report
Celldex Therapeutics, Inc. (CLDX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Celldex Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Development of therapeutic antibodies targeting mast cell biology for severe inflammatory and autoimmune diseases
- • New emphasis on bispecific antibody platform, highlighted by CDX-622 targeting TSLP and SCF with Phase 1 studies initiated in 2024-2026
- • Strategic shift toward building a fully integrated, commercial-stage biopharma company with potential for retaining full economic rights or forming partnerships
- • Phase 3 enrollment completed for Barzolvolimab in Chronic Spontaneous Urticaria; topline data expected Q4 2026
- • Notable sustained efficacy: over 40% of CSU patients maintained complete response at 76 weeks post-dosing with Barzolvolimab
Management Discussion & Analysis
- • No revenue or YoY change disclosed; focus on clinical R&D for barzolvolimab and CDX-622
- • R&D expenses $245.1M in 2025 vs $163.6M in 2024 and $118.0M in 2023, driven by barzolvolimab program ($198.3M in 2025)
- • Barzolvolimab program best performing segment with $198.3M R&D spend; CDX-622 at $19.0M; no revenue or profit data provided
- • No cash flow, buybacks, dividends, or capex details disclosed in provided text
- • Management expects topline Phase 3 data for CSU indication in Q4 2026; key risk: lengthy, costly clinical trials, uncertain regulatory approvals, and capital needs
Risk Factors
- • FDA regulatory delays from recent 43-day government shutdown Oct-Nov 2025 impacting review timelines
- • Global supply chain disruptions threatening clinical trial material supplies and contract manufacturing capacity
- • Clinical trial enrollment challenges due to patient recruitment difficulties risking costly delays or trial cancellations
- • Market competition risk from other monoclonal antibody developers with more advanced or approved therapies
- • $52.5M milestone payment under Kolltan merger may require dilutive stock issuance or additional debt funding
Celldex Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$2M
▼ -78.0% YoY
Net Income
-$259M
▼ -63.9% YoY
Operating Margin
-18599.8%
▼ -1582092bp YoY
Net Margin
-16748.0%
▼ -1449927bp YoY
ROE
-49.1%
▼ -2795bp YoY
Total Assets
$583M
▼ -26.4% YoY
EPS (Diluted)
$-3.90
▼ -59.2% YoY
Operating Cash Flow
-$211M
▼ -33.7% YoY
Source: XBRL data from Celldex Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Celldex Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.